Higher fluoride levels in public drinking water during pregnancy may be linked to differences in children's cognition scores, NIH-funded study finds
Peer-Reviewed Publication
Updates every hour. Last Updated: 31-Oct-2026 13:15 ET (31-Oct-2026 17:15 GMT/UTC)
The global community should work at establishing an array of new international legal rules to protect the health of fishing stocks, new research says.
Pregnant mothers who lived in neighborhoods where public drinking water fluoride levels were near or above the current U.S. recommended levels, tended to have children who scored lower on tests of fluid reasoning as fluoride levels increased, according to a new study supported by the National Institutes of Health’s Environmental influences on Child Health Outcomes (ECHO) Program.
In collaboration with partners, researchers at Kaunas University of Technology (KTU) have developed new hybrid compounds that, in laboratory studies, were shown to simultaneously reduce the viability of aggressive cancer cells and inhibit the growth of certain bacteria and fungi.
Most scientific research into snoring is aimed at treating sleep apnea, but snoring not caused by sleep apnea can still be debilitating. In Physics of Fluids, researchers developed a 3D model of the upper airway, complete with dynamic airflows, soft tissues, and sound generation, with the goal of understanding how these elements are related. They simulated the movement of air through the mouth, watching closely for any sound-producing vibrations, and found that the loudest sounds resulted from unsteady airflow across the soft tissues of the mouth, hinting at possible anti-snoring solutions.
More than two-thirds of adults (68.6 percent) reported viewing their test results before hearing from a provider. Those who immediately viewed results were more likely to be older and female, and have a higher income, multiple chronic health conditions, higher digital literacy, and greater use of health-related social media.
Insilico Medicine has been nominated for the 2026 Prix Galien USA “Best Startup” Award for the second consecutive year. The nomination follows rentosertib’s advancement into Phase III clinical development, the company’s listing on the Hong Kong Stock Exchange, and agreements announced in 2026 representing approximately $10 billion in aggregate potential value.